CytoMed announces promising preclinical study results on donor-derived γδ T cell therapy for acute myeloid leukemia in collaboration with MDACC.
Quiver AI Summary
CytoMed Therapeutics Limited, a clinical-stage biopharmaceutical company based in Singapore, has announced the publication of a preclinical study that highlights the potential of its allogeneic γδ T cell therapy (CTM-GDT) for treating acute myeloid leukemia (AML). This study, conducted in collaboration with The University of Texas, MD Anderson Cancer Center, suggests that donor-derived Vγ9Vδ2 T cells may serve as an effective "off-the-shelf" immunotherapy approach for AML. The research supports further clinical investigations into the use of these γδ T cells for AML and other cancers, as the company aims to advance its therapy into clinical trials following its lead product, CAR-γδ T cells (CTM-N2D), which is currently in a Phase 1 trial in Singapore. CytoMed, founded in 2018 and spun off from Singapore’s A*STAR, is focused on developing novel cell-based immunotherapies to address various cancers.
Potential Positives
- Announcement of a successful preclinical study on donor-derived γδ T cell therapy for acute myeloid leukemia, highlighting promising results and potential for treating this cancer type.
- Collaboration with The University of Texas, MD Anderson Cancer Center, enhances credibility and expertise in research, potentially attracting further partnerships and funding.
- Plan to advance γδ T cell-based products into clinical trials showcases commitment to innovation and expanding treatment options for patients with limited alternatives.
- Publication of research findings in a freely accessible format increases visibility and supports the company's position as a leader in novel immunotherapy development.
Potential Negatives
- The release primarily focuses on a preclinical study, which may indicate that CytoMed's products are still in the early stages of development and not yet ready for market, potentially delaying revenue generation.
- The mention of risks and uncertainties in forward-looking statements suggests that there are significant challenges ahead for the company, which could deter investor confidence.
- There is an emphasis on the company's reliance on partnerships, such as with MD Anderson, which may raise concerns about its ability to independently advance its therapies.
FAQ
What is CytoMed Therapeutics Limited's focus?
CytoMed focuses on developing affordable donor-derived cell-based immunotherapies for a range of cancers, including blood and solid tumors.
What notable collaboration has CytoMed announced?
CytoMed announced a collaboration with The University of Texas, MD Anderson Cancer Center for a preclinical study on γδ T cell therapy.
What is the significance of the recent research publication?
The publication suggests that CytoMed’s γδ T cell therapy has promising potential for treating acute myeloid leukemia (AML).
What are the next steps for CytoMed?
CytoMed plans to advance their γδ T cell therapy into clinical trials in Southeast Asia, following their leading product's Phase 1 trial.
When was CytoMed Therapeutics Limited incorporated?
CytoMed was incorporated in 2018 and spun off from Singapore's Agency for Science, Technology and Research (A*STAR).
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$GDTC Hedge Fund Activity
We have seen 2 institutional investors add shares of $GDTC stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC added 10,419 shares (+60.4%) to their portfolio in Q2 2025, for an estimated $23,442
- UBS GROUP AG added 3,134 shares (+21.7%) to their portfolio in Q2 2025, for an estimated $7,051
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SINGAPORE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to announce the publication of a preclinical study, in a research article entitled “ Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “off-the-shelf” Immunotherapy Approach ”. The study results from this collaborative research with The University of Texas, MD Anderson Cancer Center (MDACC), are suggesting the promising potential of CytoMed’s allogeneic γδ T cell therapy (CTM-GDT) for treating acute myeloid leukemia (AML). This collaboration with MDACC is under a previously announced research agreement in May 2023. The research article is now publicly and freely online at Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “Off-the-Shelf” Immunotherapy Approach .
“These findings provide the rationale for further clinical study of allogeneic donor-derived γδ T cells in treating AML as well as other cancers. It will facilitate our endeavour to advance our next γδ T cell-based product into clinical trial after our leading product CAR-γδ T cells (CTM-N2D), which is currently undergoing a Phase 1 clinical trial in Singapore.” said Dr. Zeng Jieming, M.D., Ph.D., Chief Scientific and Medical Officer of CytoMed and co-author of the paper.
Mr. Peter Choo, Chairman of CytoMed commented, “This research provides more evidence for applying allogeneic γδ T cells to hematologic malignancies and we are planning to move into clinical trials in Southeast Asia and bring novel immunotherapy options to patients with limited treatment alternatives.”
About CytoMed Therapeutics Limited (CytoMed)
Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours. For more information, please visit www.cytomed.sg and follow us on Twitter (“X”) @CytomedSG , on LinkedIn , and Facebook .
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company’s current and future pre-clinical studies and clinical trials and the Company’s R&D programs; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company’s ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.
Contact:
CytoMed Therapeutics Limited
[email protected]
Attention: Evelyn Tan, Chief Corporate Officer
